AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Limited has established a Clinical Advisory Board composed of renowned Idiopathic Pulmonary Fibrosis (IPF) experts to advance its lead drug candidate AD-214 into Phase II clinical trials, aiming for commercialization. The board members and a newly appointed specialist adviser for translational science bring extensive experience in IPF clinical trials and research, strengthening the company’s strategy for developing AD-214. This move signifies AdAlta’s commitment to addressing the needs of over 500,000 IPF patients worldwide with this potentially first-in-class therapeutic option.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
